Avidity Biosciences Inc. (RNA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Avidity Biosciences Inc. (RNA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

26.99

-1.42 (-5.00%)

At close: Jan 14, 2025, 3:59 PM

27.00

0.04%

Pre-market Jan 15, 2025, 07:00 AM EST

undefined% (undefined)

Bid	26.25
Market Cap	3.22B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.88
PE Ratio (ttm)	-9.37
Forward PE	n/a
Analyst	Buy

Ask	38.13
Volume	1,351,423
Avg. Volume (20D)	1,172,631
Open	28.79
Previous Close	28.41
Day's Range	26.74 - 29.04
52-Week Range	9.93 - 56.00
Beta	undefined

About RNA

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to tr...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 12, 2020

Employees 253

Stock Exchange NASDAQ

Ticker Symbol RNA

Website https://www.aviditybiosciences.com

Analyst Forecast

According to 10 analyst ratings, the average rating for RNA stock is "Buy." The 12-month stock price forecast is $63, which is an increase of 133.42% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Avidity Biosciences Inc. is scheduled to release its earnings on Feb 26, 2025, during market hours.
Analysts project revenue of $1.62M, reflecting a -26.13% YoY shrinking and earnings per share of -0.78, making a -1.27% decrease YoY.

Why Price Moved

2 months ago · Source

+12.35%

Avidity Biosciences shares are trading higher. Nee... Unlock content with Pro Subscription

5 months ago · Source

-4.76%

Avidity Biosciences shares are trading lower after the company proposed a $250 million public offering of common stock.

News

1 month ago · seekingalpha.com

Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases

Avidity Biosciences' AOC platform targets genetic diseases by combining monoclonal antibodies with oligonucleotide therapies, overcoming traditional delivery limitations. Del-brax (AOC 1020) for FSHD ...

2 months ago · zacks.com

RNA Stock Hits Record High on Entering the Cardiac Disease Space

Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.

2 months ago · investors.com

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News

Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space. The post Avidity Bio Has Surged 416% This Year — And That's Before Today'...

2 months ago · zacks.com

Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates

Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.71 per share a year ago.

2 months ago · zacks.com

Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for

Avidity Biosciences (RNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.